Solid phase assisted synthesis of HIV-1 protease inhibitors.: Expedient entry to unsymmetrical substitution of a C2 symmetric template

被引:12
作者
Oscarsson, K
Classon, B
Kvarnström, I
Hallberg, A
Samuelsson, B [1 ]
机构
[1] Stockholm Univ, Arrhenius Lab, Dept Organ Chem, SE-10691 Stockholm, Sweden
[2] Linkoping Univ, Dept Chem, S-58183 Linkoping, Sweden
[3] Uppsala Univ, BMC, Dept Organ Pharmaceut Chem, S-75123 Uppsala, Sweden
[4] Medivir AB, SE-14144 Huddinge, Sweden
关键词
HIV; inhibitor; protease; solid phase;
D O I
10.1139/cjc-78-6-829
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A solid phase synthesis has been developed leading up to unsymmetrical HIV-1 protease inhibitors that are not readily available by conventional solution phase chemistry (18a-g). To prepare these compounds the hydroxyl group of (1S,2R)-(-)-cis-1-phthalimido-2-indanol (3) was coupled to a Merrifield resin via a dihydropyrane linker. Cleavage of the phthalimido protecting group and reaction of the liberated amine with the bis-activated symmetrical diacid 15 resulted in the resin bound amide 16. Coupling of 16 with amino acids and amines followed by hydrolysis produced the desired unsymmetrical products 18a-g from which potent HIV-1 protease inhibitors were identified, e.g., 18e (k(i) = 0.1 nM), 18a (k(i) = 0.2 nM) and 18c (k(i) = 2 nM).
引用
收藏
页码:829 / 837
页数:9
相关论文
共 35 条
[1]   Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors.: Use of L-mannaric acid as a peptidomimetic scaffold [J].
Alterman, M ;
Björsne, M ;
Mühlman, A ;
Classon, B ;
Kvarnström, I ;
Danielson, H ;
Markgren, PO ;
Nillroth, U ;
Unge, T ;
Hallberg, A ;
Samuelsson, B .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (20) :3782-3792
[2]   ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
BARRESINOUSSI, F ;
CHERMANN, JC ;
REY, F ;
NUGEYRE, MT ;
CHAMARET, S ;
GRUEST, J ;
DAUGUET, C ;
AXLERBLIN, C ;
VEZINETBRUN, F ;
ROUZIOUX, C ;
ROZENBAUM, W ;
MONTAGNIER, L .
SCIENCE, 1983, 220 (4599) :868-871
[3]  
*CD ROMPP CHEM LEX, 1995, VERS 1 0
[4]  
CLERCQ ED, 1995, J MED CHEM, V38, P2491, DOI DOI 10.1021/jm00014a001
[5]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[6]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[7]  
Danielson H, 1998, ADV EXP MED BIOL, V436, P99
[8]  
Deeks S G, 1997, AIDS Clin Rev, P145
[9]   L-735,524 - THE DESIGN OF A POTENT AND ORALLY BIOAVAILABLE HIV PROTEASE INHIBITOR [J].
DORSEY, BD ;
LEVIN, RB ;
MCDANIEL, SL ;
VACCA, JP ;
GUARE, JP ;
DARKE, PL ;
ZUGAY, JA ;
EMINI, EA ;
SCHLEIF, WA ;
QUINTERO, JC ;
LIN, JH ;
CHEN, IW ;
HOLLOWAY, MK ;
FITZGERALD, PMD ;
AXEL, MG ;
OSTOVIC, D ;
ANDERSON, PS ;
HUFF, JR .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (21) :3443-3451
[10]   DESIGN, ACTIVITY, AND 2.8 A CRYSTAL-STRUCTURE OF A C2 SYMMETRICAL INHIBITOR COMPLEXED TO HIV-1 PROTEASE [J].
ERICKSON, J ;
NEIDHART, DJ ;
VANDRIE, J ;
KEMPF, DJ ;
WANG, XC ;
NORBECK, DW ;
PLATTNER, JJ ;
RITTENHOUSE, JW ;
TURON, M ;
WIDEBURG, N ;
KOHLBRENNER, WE ;
SIMMER, R ;
HELFRICH, R ;
PAUL, DA ;
KNIGGE, M .
SCIENCE, 1990, 249 (4968) :527-533